{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:08:04Z","timestamp":1779358084867,"version":"3.51.4"},"reference-count":43,"publisher":"Wiley","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["EFS2","EFSA Journal"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Abstract Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on beta\u2010nicotinamide mononucleotide (\u03b2\u2010NMN) as a novel food (NF) pursuant to Regulation (EU) 2015\/2283, including an evaluation of the safety of its use in food supplements as a source of niacin, and the bioavailability of nicotinamide from this source, in the context of Directive 2002\/46\/EC. The NF consists of chemically synthesised \u03b2\u2010NMN and is intended for use in food supplements as a source of niacin up to 300\u2009mg\/day. The target population is adults, excluding pregnant and lactating women. The identity, production process, composition and specifications of the NF do not raise safety concerns. A human intervention study comparing the relative bioavailability of \u03b2\u2010NMN and nicotinamide in equimolar amounts supported the use of a conversion factor (CF) of 1. On this basis, the proposed maximum intake corresponds to 109.7\u2009mg\/day of nicotinamide. This amount is approximately five times the population reference intake (PRI) of niacin for adults but remains below the upper level (UL) of 900\u2009mg\/day for nicotinamide. No concerns were identified regarding genotoxicity. In a 90\u2010day repeated dose oral toxicity study in rats, effect on reproductive organs were observed and the no observed adverse effect level (NOAEL) of 400\u2009mg\/kg bw per day identified, resulting in a margin of exposure (MoE) of 93. The available human study did not raise safety concerns. Based on the nature and the metabolic fate of the NF, the proposed use levels and the available human data, the calculated MoE was considered sufficient. The Panel concludes that the NF is safe under the proposed conditions of use for the adult population, excluding pregnant and lactating women and that the NF constitutes a bioavailable source of nicotinamide, a form of niacin.<\/jats:p>","DOI":"10.2903\/j.efsa.2026.10007","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:04:41Z","timestamp":1778493881000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety of beta\u2010nicotinamide mononucleotide (\u03b2\u2010NMN) pursuant the regulation (EU) 2015\/2283 and the bioavailability of nicotinamide from this source in the context of Directive 2002\/46\/EC"],"prefix":"10.2903","volume":"24","author":[{"name":"EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Turck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Bohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monta\u00f1a","family":"C\u00e1mara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Castenmiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefaan","family":"De Henauw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngeles","family":"Jos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Maciuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge","family":"Mangelsdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Breige","family":"McNulty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Androniki","family":"Naska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Pentieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Siani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Thies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Aguilera\u2010G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cubadda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Gundert\u2010Remy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Marcon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry J.","family":"McArdle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Neuh\u00e4user\u2010Berthold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Prieto","family":"Maradona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros","family":"Siskos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Beneventi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maura","family":"Magani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen Ildico","family":"Hirsch\u2010Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"10.2903\/j.efsa.2026.10007_ref1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/ggi.14513","article-title":"Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: A prospective, placebo\u2010controlled, double\u2010blind study","volume":"23","author":"Akasaka","year":"2023","journal-title":"Geriatrics & Gerontology International"},{"key":"#cr-split#-10.2903\/j.efsa.2026.10007_ref2.1","unstructured":"EFSA (European Food Safety Authority) . (2021). Administrative guidance for the preparation of applications on novel foods pursuant to Article 10 of Regulation"},{"key":"#cr-split#-10.2903\/j.efsa.2026.10007_ref2.2","unstructured":"(EU) 2015\/2283. EFSA Supporting Publications, 18(3), 6488E. https:\/\/doi.org\/10.2903\/sp.efsa.2021.EN\u20106488"},{"key":"10.2903\/j.efsa.2026.10007_ref3","doi-asserted-by":"crossref","unstructured":"EFSA ANS Panel (Panel on Food Additives and Nutrient Sources added to Food) . (2021). Guidance on safety evaluation of sources of nutrients and bioavailability of nutrient from the sources (Revision 1). EFSA Journal, 19(3), 6552. https:\/\/doi.org\/10.2903\/j.efsa.2021.6552","DOI":"10.2903\/j.efsa.2021.6552"},{"key":"10.2903\/j.efsa.2026.10007_ref4","doi-asserted-by":"crossref","unstructured":"EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens) .. (2013). Scientific opinion on dietary reference values for energy. EFSA Journal, 11(1), 3005. https:\/\/doi.org\/10.2903\/j.efsa.2013.3005","DOI":"10.2903\/j.efsa.2013.3005"},{"key":"10.2903\/j.efsa.2026.10007_ref5","doi-asserted-by":"crossref","unstructured":"EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies) . (2014). Scientific opinion on dietary reference values for niacin. EFSA Journal, 12(7), 3759. https:\/\/doi.org\/10.2903\/j.efsa.2014.3759","DOI":"10.2903\/j.efsa.2014.3759"},{"key":"#cr-split#-10.2903\/j.efsa.2026.10007_ref6.1","unstructured":"EFSA NDA Panel (EFSA Panel on Nutrition, Novel foods and Food allergens) . (2019). Scientific Opinion on the safety of nicotinamide riboside chloride as a novel food pursuant to Regulation"},{"key":"#cr-split#-10.2903\/j.efsa.2026.10007_ref6.2","doi-asserted-by":"crossref","unstructured":"(EU) 2015\/2283 and bioavailability of nicotinamide from this source, in the context of Directive 2002\/46\/EC. EFSA Journal, 17(8), 5775. https:\/\/doi.org\/10.2903\/j.efsa.2019.5775","DOI":"10.2903\/j.efsa.2019.5775"},{"key":"#cr-split#-10.2903\/j.efsa.2026.10007_ref7.1","unstructured":"EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies) . (2021). Guidance on the preparation and submission of an application for authorisation of a novel food in the context of Regulation"},{"key":"#cr-split#-10.2903\/j.efsa.2026.10007_ref7.2","doi-asserted-by":"crossref","unstructured":"(EU) 2015\/2283 (Revision 1). EFSA Journal, 19(3), 6555. https:\/\/doi.org\/10.2903\/j.efsa.2021.6555","DOI":"10.2903\/j.efsa.2021.6555"},{"key":"#cr-split#-10.2903\/j.efsa.2026.10007_ref8.1","unstructured":"EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens) . (2021). Scientific Opinion on the extension of use of nicotinamide riboside chloride as a novel food pursuant to Regulation"},{"key":"#cr-split#-10.2903\/j.efsa.2026.10007_ref8.2","doi-asserted-by":"crossref","unstructured":"(EU) 2015\/2283. EFSA Journal, 19(11), 6843. https:\/\/doi.org\/10.2903\/j.efsa.2021.6843","DOI":"10.2903\/j.efsa.2021.6843"},{"key":"10.2903\/j.efsa.2026.10007_ref9","doi-asserted-by":"crossref","unstructured":"EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens) . (2024). Guidance on scientific principles and data requirements for the safety and relative bioavailability assessment of new micronutrient sources. EFSA Journal, 22(8), 8946. https:\/\/doi.org\/10.2903\/j.efsa.2024.8946","DOI":"10.2903\/j.efsa.2024.8946"},{"key":"10.2903\/j.efsa.2026.10007_ref10","doi-asserted-by":"crossref","unstructured":"EFSA Scientific Committee . (2021). Guidance on technical requirements for regulated food and feed product applications to establish the presence of small particles including nanoparticles. EFSA Journal, 19(8), 6769. https:\/\/doi.org\/10.2903\/j.efsa.2021.6769","DOI":"10.2903\/j.efsa.2021.6769"},{"key":"10.2903\/j.efsa.2026.10007_ref11","doi-asserted-by":"crossref","unstructured":"Fukamizu, Y., Uchida, Y., Shigekawa, A., Sato, T., Kosaka, H., & Sakurai, T. (2022). Safety evaluation of \u03b2\u2010nicotinamide mononucleotide oral administration in healthy adult men and women. Scientific Reports, 12, 14442. https:\/\/doi.org\/10.1038\/s41598\u2010022\u201018272\u2010y","DOI":"10.1038\/s41598-022-18272-y"},{"key":"10.2903\/j.efsa.2026.10007_ref12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s42255-018-0009-4","article-title":"Slc12a8 is a nicotinamide mononucleotide transporter","volume":"1","author":"Grozio","year":"2019","journal-title":"Nature Metabolism"},{"key":"10.2903\/j.efsa.2026.10007_ref13","doi-asserted-by":"crossref","unstructured":"Huang, H. (2022). A multicentre, randomised, double blind, parallel design, placebo controlled study to evaluate the efficacy and safety of Uthever\u00ae (NMN supplement), an orally administered supplementation in middle aged and older adults. Frontiers in Aging, 3, 851698. https:\/\/doi.org\/10.3389\/fragi.2022.851698","DOI":"10.3389\/fragi.2022.851698"},{"key":"10.2903\/j.efsa.2026.10007_ref14","doi-asserted-by":"crossref","unstructured":"Igarashi, M., Nakagawa\u2010Nagahama, Y., Miura, M., Kashiwabara, K., Yaku, K., Sawada, M., Sekine, R., Fukamizu, Y., Sato, T., Sakurai, T., Sato, J., Ino, K., Kubota, N., Nakagawa, T., Kadowaki, T., & Yamauchi, T. (2022). Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. NPJ Aging, 8(5), 5. https:\/\/doi.org\/10.1038\/s41514\u2010022\u201000084\u2010z","DOI":"10.1038\/s41514-022-00084-z"},{"key":"10.2903\/j.efsa.2026.10007_ref15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1507\/endocrj.EJ19-0313","article-title":"Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men","volume":"67","author":"Irie","year":"2020","journal-title":"Endocrine Journal"},{"key":"10.2903\/j.efsa.2026.10007_ref16","doi-asserted-by":"crossref","unstructured":"Katayoshi, T., Uehata, S., Nakashima, N., Nakajo, T., Kitajima, N., Kageyama, M., & Tsuji\u2010Naito, K. (2023). Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long\u2010term nicotinamide mononucleotide supplementation: A randomized, double\u2010blind, placebo\u2010controlled trial. Scientific Reports, 13, 2786. https:\/\/doi.org\/10.1038\/s41598\u2010023\u201029787\u20103","DOI":"10.1038\/s41598-023-29787-3"},{"key":"10.2903\/j.efsa.2026.10007_ref17","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3177\/jnsv.62.272","article-title":"\u03b2\u2010Nicotinamide mononucleotide, an anti\u2010aging candidate compound, is retained in the body for longer than nicotinamide in rat","volume":"62","author":"Kawamura","year":"2016","journal-title":"Journal of Nutritional Science and Vitaminology"},{"issue":"17","key":"10.2903\/j.efsa.2026.10007_ref18","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1873-3468.14698","article-title":"Host\u2010microbiome interactions in nicotinamide mononucleotide (NMN) deamidation","volume":"597","author":"Kim","year":"2023","journal-title":"FEBS Letters"},{"issue":"6","key":"10.2903\/j.efsa.2026.10007_ref19","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.cmet.2016.09.013","article-title":"Long\u2010term administration of nicotinamide mononucleotide mitigates age\u2010associated physiological decline in mice","volume":"24","author":"Mills","year":"2016","journal-title":"Cell Metabolism"},{"key":"10.2903\/j.efsa.2026.10007_ref20","unstructured":"OECD (Organisation for Economic Co\u2010Operation and Development) . (1997). Test no. 471: Bacterial reverse mutation test. OECD guidelines for the testing of chemicals, Section\u00a04 (p. 11, Corrected 2020). OECD Publishing. https:\/\/doi.org\/10.1787\/9789264071247\u2010en"},{"key":"10.2903\/j.efsa.2026.10007_ref21","unstructured":"OECD (Organisation for Economic Co\u2010Operation and Development) . (2016a). Test no. 473: In\u00a0vitro mammalian chromosomal aberration test, OECD guidelines for the testing of chemicals, Section\u00a04. OECD Publishing. https:\/\/doi.org\/10.1787\/9789264264649\u2010en"},{"key":"10.2903\/j.efsa.2026.10007_ref22","unstructured":"OECD (Organisation for Economic Co\u2010Operation and Development) . (2016b). Test no. 475: Mammalian bone marrow chromosomal aberration test, OECD guidelines for the testing of chemicals, Section\u00a04. OECD Publishing. https:\/\/doi.org\/10.1787\/9789264264786\u2010en"},{"key":"10.2903\/j.efsa.2026.10007_ref23","unstructured":"OECD (Organisation for Economic Co\u2010Operation and Development) . (2023). Test no. 487: In\u00a0vitro mammalian cell micronucleus test. OECD guidelines for the testing of chemicals, Section\u00a04 (p. 23). OECD Publishing. https:\/\/doi.org\/10.1787\/9789264264861\u2010en"},{"key":"10.2903\/j.efsa.2026.10007_ref24","doi-asserted-by":"crossref","unstructured":"Okabe, K., Yaku, K., Uchida, Y., Fukamizu, Y., Sato, T., Sakurai, T., Tobe, K., & Nakagawa, T. (2022). Oral administration of nicotinamide mononucleotide is safe and efficiently increases blood nicotinamide adenine dinucleotide levels in healthy subjects. Frontiers. Nutrition, 9, 868640. https:\/\/doi.org\/10.3389\/fnut.2022.868640","DOI":"10.3389\/fnut.2022.868640"},{"key":"10.2903\/j.efsa.2026.10007_ref25","doi-asserted-by":"crossref","unstructured":"Poddar, S. K., Sifat, A. E., Haque, S., Nahid, N. A., Chowdhury, S., & Mehedi, I. (2019). Nicotinamide mononucleotide: Exploration of diverse therapeutic applications of a potential molecule. Biomolecules, 9(1), 34. https:\/\/doi.org\/10.3390\/biom9010034","DOI":"10.3390\/biom9010034"},{"key":"10.2903\/j.efsa.2026.10007_ref26","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s42255-019-0085-0","article-title":"Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter","volume":"1","author":"Schmidt","year":"2019","journal-title":"Nature Metabolism"},{"key":"10.2903\/j.efsa.2026.10007_ref27","unstructured":"Scientific Committee on Food (SCF) . (2022). Opinion of the Scientific Committee on Food on the upper tolerable intake of nicotinic acid and nicotinamide (niacin). http:\/\/ec.europa.eu\/food\/fs\/sc\/scf\/out80j_en.pdf"},{"key":"10.2903\/j.efsa.2026.10007_ref28","unstructured":"Unpublished study . (2021a). Bacterial reverse mutation test (GLP, OECD TG 471)."},{"key":"10.2903\/j.efsa.2026.10007_ref29","unstructured":"Unpublished study . (2021b). In vitro mammalian chromosomal aberration test (GLP, OECD TG 473)."},{"key":"10.2903\/j.efsa.2026.10007_ref30","unstructured":"Unpublished study . (2021c). In vivo mammalian bone marrow chromosomal aberration test (GLP, OECD TG 475)."},{"key":"10.2903\/j.efsa.2026.10007_ref31","unstructured":"Unpublished study . (2021d). 90\u2010day repeated dose oral toxicity study with a 28\u2010day recovery period (GLP, OECD TG 408)."},{"key":"10.2903\/j.efsa.2026.10007_ref32","unstructured":"Unpublished study . (2021e). A multicentre, randomized, double blind, parallel design, placebo controlled study to evaluate the efficacy and safety of Uthever (NMN supplement), an orally administered supplementation in middle aged and older adults."},{"key":"10.2903\/j.efsa.2026.10007_ref33","unstructured":"Unpublished study . (2023a). Hydrolysis of the \u03b2\u2010NMN as a function of pH."},{"key":"10.2903\/j.efsa.2026.10007_ref34","unstructured":"Unpublished study . (2023b). In vitro mammalian cell micronucleus test (GLP, OECD TG 487)."},{"key":"10.2903\/j.efsa.2026.10007_ref35","unstructured":"Unpublished study . (2024a). Assessment of the permeability of NMN and NAM across the Caco\u20102 cell monolayer."},{"key":"10.2903\/j.efsa.2026.10007_ref36","unstructured":"Unpublished study . (2024b). In vivo pharmacokinetic study in male Sprague\u2010Dawley rats."},{"key":"10.2903\/j.efsa.2026.10007_ref37","unstructured":"Unpublished study . (2025). Human intervention study comparing \u03b2\u2010NMN and nicotinamide."},{"key":"10.2903\/j.efsa.2026.10007_ref38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11357-022-00705-1","article-title":"The efficacy and safety of \u03b2\u2010nicotinamide mononucleotide (NMN) supplementation in healthy middle\u2010aged adults: A randomized, multicenter, double\u2010blind, placebo\u2010controlled, parallel\u2010group, dose\u2010dependent clinical trial","volume":"45","author":"Yi","year":"2023","journal-title":"Geroscience"},{"issue":"3","key":"10.2903\/j.efsa.2026.10007_ref39","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.cmet.2017.11.002","article-title":"NAD+ intermediates: The biology and therapeutic potential of NMN and NR","volume":"27","author":"Yoshino","year":"2018","journal-title":"Cell Metabolism"}],"container-title":["EFSA Journal"],"original-title":[],"link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.2903\/j.efsa.2026.10007","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.2903\/j.efsa.2026.10007\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:30:51Z","timestamp":1779355851000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.2903\/j.efsa.2026.10007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.2903\/j.efsa.2026.10007","relation":{},"ISSN":["1831-4732","1831-4732"],"issn-type":[{"value":"1831-4732","type":"print"},{"value":"1831-4732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}